- Home
- DSGN vs BBOT Comparison
DSGN vs BBOT Comparison
Compare DSGN & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- BBOT
- Stock Information
- Founded
- DSGN 2017
- BBOT N/A
- Country
- DSGN United States
- BBOT United States
- Employees
- DSGN N/A
- BBOT N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- BBOT Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- BBOT Health Care
- Exchange
- DSGN Nasdaq
- BBOT Nasdaq
- Market Cap
- DSGN 208.9M
- BBOT 250.4M
- IPO Year
- DSGN 2021
- BBOT N/A
- Fundamental
- Price
- DSGN $5.26
- BBOT $8.84
- Analyst Decision
- DSGN
- BBOT Buy
- Analyst Count
- DSGN 0
- BBOT 1
- Target Price
- DSGN N/A
- BBOT $25.00
- AVG Volume (30 Days)
- DSGN 141.5K
- BBOT 174.7K
- Earning Date
- DSGN 08-07-2025
- BBOT 01-01-0001
- Dividend Yield
- DSGN N/A
- BBOT N/A
- EPS Growth
- DSGN N/A
- BBOT N/A
- EPS
- DSGN N/A
- BBOT N/A
- Revenue
- DSGN N/A
- BBOT N/A
- Revenue This Year
- DSGN N/A
- BBOT N/A
- Revenue Next Year
- DSGN N/A
- BBOT N/A
- P/E Ratio
- DSGN N/A
- BBOT N/A
- Revenue Growth
- DSGN N/A
- BBOT N/A
- 52 Week Low
- DSGN $2.60
- BBOT $8.70
- 52 Week High
- DSGN $7.77
- BBOT $12.50
- Technical
- Relative Strength Index (RSI)
- DSGN 61.90
- BBOT N/A
- Support Level
- DSGN $4.68
- BBOT N/A
- Resistance Level
- DSGN $5.60
- BBOT N/A
- Average True Range (ATR)
- DSGN 0.39
- BBOT 0.00
- MACD
- DSGN 0.04
- BBOT 0.00
- Stochastic Oscillator
- DSGN 79.95
- BBOT 0.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.